Articles tagged with Cervical Cancer
The bivalent HPV vaccine has been shown to protect against anal HPV 16 and 18 infections, preventing nearly 84% of cases in women without prior exposure. The vaccine also offers cross-protective efficacy against other cancer-causing HPV types, suggesting a broader potential for prevention of HPV-associated cancers.
A CDC study found that primary care providers continue to recommend annual cervical cancer screening, despite guidelines suggesting a less frequent screening interval. The study suggests that establishing a history of normal Pap tests is crucial in making guideline-supported screening interval recommendations.
A lack of understanding about HPV vaccination and its link to future cervical screening has been found among parents and girls in the UK. Despite being effective against two high-risk HPV types, vaccinated individuals still require regular cervical screenings to protect against other strains that can cause cancer.
The Cervical Cancer Prevention Program in Zambia has provided services to over 58,000 women, saving lives and establishing a new solution for routine prevention intervention in resource-constrained environments.
Researchers are developing an oral vaccine for cervical cancer and a combination prostate cancer vaccine, aiming to improve vaccination accessibility and affordability. The vaccines use nanoparticle-based Human Papillomavirus (HPV) formulations, potentially reducing costs and enabling mass vaccinations.
Researchers discovered that lopinavir selectively kills HPV-infected non-cancerous cells while leaving healthy cells relatively unaffected. The study suggests a potential treatment for HPV-related cervical cancer using locally applied lopinavir cream or pessary.
A new study found that radiologists using MRI can correctly identify the primary site of cancer in 79% of cases, even when biopsy results are inconclusive. This improves patient outcomes by providing more accurate treatment options.
A study of 435 women who underwent treatment for precancerous cervical lesions found that a three-cytological-smears post-treatment surveillance strategy is effective in identifying women at long-term risk of cervical cancer. By adding high-risk human papillomavirus (hrHPV) testing, the need for subsequent screens can be reduced.
Researchers at Tufts University School of Medicine have developed a protein-based inhibitor that blocks HPV protein expression in cell culture, paving the way for a topical treatment. The inhibitor, E2R, prevents viral gene transcription and has shown promise against various strains of HPV, including high-risk and low-risk types.
A study found that extending the HPV vaccine dosing schedule to every 3 months was comparable to the standard schedule in terms of antibody concentration levels. This alternative schedule may provide a more feasible option for expanding vaccine use in developing countries.
A study by Georgetown University Medical Center researchers suggests that activation of the beta-catenin oncogene is key to understanding why many women with HPV infection do not develop cervical cancer. The discovery could lead to new screening methods and therapeutic approaches, including targeting the Wnt pathway.
A recent study found that approximately 50% of men in the general population are infected with human papillomavirus (HPV), a virus known for causing cervical cancer in women. The study also revealed high incidence and transmission rates, particularly among men with multiple partners.
A new study led by UCSF found that the HPV vaccine can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine. The vaccine also showed a nearly 66 percent effectiveness rate in the general population of young men, regardless of prior exposure.
A study by St. Michael's Hospital found that only one in five South Asian immigrants over 50 had a recent Pap test, compared to 79% of Canadian-born women with high-income neighborhoods and primary care doctors. The low screening rates may be due to cultural factors and lack of awareness about the importance of the test.
Magnetic nanoparticles can detect cervical cancer by trapping antibodies, offering earlier screening and treatment. Similarly, these nanoparticles can detect E. coli infections at lower bacterial cell counts, halting disease spread faster.
Scientists have discovered how the human papilloma virus (HPV) triggers cancer in the cervix and mouth, potentially leading to new treatments. The study found that HPV activates a protein called Cdc42, which is already implicated in various cancers, including tumour spread.
The Cervical Cancer-Free America program aims to raise awareness and increase screenings for cervical cancer, targeting disadvantaged communities. With the support of a $150,000 grant, Indiana will implement initiatives to reduce HPV infection rates and increase vaccination rates, ultimately aiming to eliminate cervical cancer.
A recent study found that fewer than 30% of eligible young women choose to receive the HPV vaccine to prevent cervical cancer. The majority of those who start the vaccination process fail to complete the recommended three doses. African-American women are less likely to complete all three doses compared to white women.
A recent study found that targeted human papillomavirus (HPV) vaccination in men who have sex with men is a cost-effective intervention against anal cancer. The quadrivalent vaccine has demonstrated high efficacy against anal lesions and genital warts in young MSM. Vaccination at ages 12-26 years without previous exposure to HPV-target...
A study found that an annual conventional Pap smear is a cost-effective strategy for follow-up after cervical lesion treatment. This approach reduced expected cervical cancer deaths by 73-77% compared to more frequent testing.
A study confirms that eight human papillomavirus (HPV) types, including HPV 16, 18, and 45, are responsible for over 90% of all cervical cancer cases worldwide. Current vaccines prevent infection by these high-risk HPV genotypes, but future type-specific screening is recommended to target the most common types.
A randomized trial found that HPV DNA-based screening and cryotherapy significantly reduced high-grade cervical cancer precursors in unscreened South African women. The study suggests that a 'screen-and-treat' approach can be an effective cervical cancer prevention strategy, especially in low-resource settings.
The survey found that interest in receiving the HPV vaccine increased if it was available free of charge, but decreased as out-of-pocket costs rose. Convenience also played a role, with many women preferring to receive the vaccine at a doctor's office rather than a local pharmacy.
Using an electronic medical record (EMR) tracking system can improve follow-up after an abnormal Pap test, leading to increased diagnostic resolution and faster treatment times. The study found that physicians who used this tracking system had significantly shorter times to diagnosis compared to traditional methods.
A new study has demonstrated that combining a specific drug with radiotherapy significantly improves treatment outcomes for cervical cancer patients. The research found that the addition of cisplatin to radiotherapy reduces the likelihood of death by 23%, leading to improved survival rates.
Scientists at the University of Cambridge have developed a vaccine to stop cancer-causing viruses that invade host cells, initiate cancer, and then disappear. The vaccine has been shown to protect against subsequent cancer development in mouse models, holding promise for preventing human cancers.
Researchers from A*STAR made three groundbreaking discoveries in fight against cancer: a mechanism to prevent metastasis, biomarkers for breast cancer, and improved detection of cervical cancer. Their work sheds light on key areas of cancer research, offering new strategies to combat this devastating disease.
The European Society for Medical Oncology (ESMO) has published updated clinical practice guidelines for cancer care, providing vital information on diagnosis, treatment plans, and follow-up. The new guidelines cover various tumor types and include expanded sections on cardiotoxicity and fertility considerations.
A community-based study found HPV DNA testing to be over 50% more sensitive than cytology testing for detecting precancers and cervical cancers. The study involved 50,000 women and revealed a significant reduction in precancer rates among HPV DNA-positive women.
Clinical guidelines recommend screening low-risk women every three years after age 30, but most primary care clinicians advocate for more frequent testing. Annual Pap testing has helped decrease cervical cancer burden, but cost-effectiveness models suggest overuse may increase costs with little improvement in outcomes.
According to a new report, only about one in three young women has received the human papillomavirus (HPV) vaccine to help prevent cervical cancer. The vaccination rate is increasing, but there is still a significant disparity in HPV vaccination rates among different racial and ethnic groups.
Research suggests extending HPV testing intervals to five years for women over 30 could significantly reduce cervical cancer cases. The study found HPV tests detect early signs of cervical cancer more accurately than current cytology screening.
Researchers at UAB found that Gardasil vaccine reduces the likelihood of HPV-related disease recurring after surgery by approximately 40 percent. This protection can provide crucial follow-up care and overall health planning for teens and women.
A new study in the Journal for Healthcare Quality reveals that P4P programs can improve quality of care, especially for selected measures like mammography and childhood immunization. Low performing physicians who used a P4P program improved significantly over time, highlighting the importance of sustaining these programs.
Researchers at UF's College of Veterinary Medicine have discovered that dolphins can harbor multiple infections of apillomaviruses, which are linked to cervical cancer in humans. The study suggests that dolphins may be an ideal model for studying human cervical cancer due to their genetic similarity to humans.
A new study published in the Journal of the National Cancer Institute found that HPV vaccination benefits decline with age and frequent screening for women over 41 is likely to be low. The study suggests that newly detected HPV infections do not progress to cervical intraepithelial neoplasia grade 2 or worse, regardless of age.
Triapine regimen provides significant reduction in cancer disease and cancer control, shows great promise for patients at high risk of relapse and death. The study's complete response rate was observed and no disease progression documented through 18 months of median follow-up.
Researchers developed a mathematical model to predict cervical cancer treatment outcomes, allowing for quicker identification of non-responding tumors. The model uses MRI scans and can provide a prediction accuracy of 90 percent for local tumor control and recurrence.
Researchers at the University of Texas Health Science Center at Houston are working on cutting-edge projects to protect girls from cervical cancer and develop new approaches for treating colon cancer. The center has received over half of the $61M awarded by CPRIT, with grants totaling $4.5M.
A new study published in The Lancet Oncology suggests that HPV DNA testing is more effective than conventional cytology screening in preventing invasive cervical cancer. The study found that HPV-based screening is more effective in detecting precancerous lesions and reducing the incidence of invasive cervical cancer, particularly in de...
The HPV-16/18 AS04-adjuvanted vaccine (Cervarix) induces a strong and sustained antibody response and has a favourable safety profile. Vaccine efficacy against incident infection with HPV-16/18 was 95% and against 12-month persistent infection was 100%.
Researchers identified specific genetic changes associated with an increased risk of relapse in cervical cancer patients. These changes are crucial steps in the progression of the disease towards an aggressive and treatment-resistant state.
Primary HPV DNA screening with cytology triage is more sensitive than conventional screening for detecting cervical lesions, especially among older women. This approach can lead to fewer colposcopy referrals and follow-up tests.
Researchers at University of Wisconsin-Madison used two FDA-approved drugs to eliminate and prevent cervical cancer in mice. The drugs, which block estrogen's ability to bind to cells, cleared precancerous growths and prevented cancer onset in mice with HPV-positive lesions.
A Dutch study of nearly 90,000 women found that liquid-based cytology is not superior to the conventional Pap test for detecting cervical cancer precursors or cancer. The study's findings provide strong evidence that liquid-based cytology performs similarly to the traditional Pap smear in a well-organized screening program.
The American College of Physicians (ACP) has issued clinical practice guidelines for treating erectile dysfunction (ED), recommending the use of phosphodiesterase type 5 (PDE-5) inhibitors and individualizing decisions on hormonal tests. For patients with stable ischemic heart disease, adding ACE inhibitors to standard care improves ou...
Common human papillomavirus (HPV) genotypes in northern India are primarily HP-16 and HP-18. These types cause 75 percent of cervical cancers in the region, according to researchers.
Researchers found that vaccinating boys would be less cost-effective than vaccinating pre-adolescent girls, with a higher cost-effectiveness ratio of $290,290 per QALY. The study suggests prioritizing HPV vaccination of girls and continued cervical cancer screening in adulthood.
The University of Alabama at Birmingham Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute to explore groundbreaking cervical cancer research, prevention, and treatment. The grant will focus on next-generation human papillomavirus (HPV) vaccines for cervical cancer prevention and test therapeu...
A study published in The Lancet Oncology found that immunodeficiency increases the risk of multiple cancers in HIV patients. Lower CD4 counts were linked to higher risks of certain cancers, while antiretroviral therapy reduced this risk. Effective cancer screening programs are recommended for HIV-positive individuals.
Vaccination against HPV, combined with national screening programmes, could lead to the eradication of cervical cancer in countries that implement such measures. HPV screening is more effective than Pap smear tests and can detect the virus in smears rather than relying on visual examination.
Cancer experts are developing a tool to work out the percentage risk a woman has of developing cervical cancer. The tool uses cervical precancer, defined as histological cervical intraepithelial neoplasia grade 3 (CIN3) or more severe, as a surrogate for cervical cancer.
The study analyzed reports of adverse events following HPV vaccination and found a higher proportion of reports of fainting and blood clots. However, the rates were still consistent with pre-licensing data and background rates of other vaccines.
People living with AIDS are at a higher risk of developing HPV-associated cancers, particularly those with lower CD4 T-cell counts. The study estimates that incidence rates increased across three periods, with the greatest risk observed in invasive anal cancer among men after the introduction of highly active antiretroviral therapy.
The Latino/a population is projected to triple by 2050, leading to a significant increase in cancer diagnoses. Improvements are needed in knowledge and access to services, particularly for breast and cervical cancers among Latinas.
A team of scientists developed a computer model that predicts cancer recurrence in an individual based on how their tumor changes size in response to the first rounds of radiation therapy. The study found that tumors with higher resistance to radiotherapy had a lower chance of reappearing years later.
The HPV-16/18 AS04-adjuvanted vaccine shows high efficacy against precancerous cervical lesions, with cross-protective efficacy against other oncogenic HPV types. The vaccine also demonstrates efficacy in universal mass vaccination and catch-up programmes, potentially reducing cervical cancer incidence.
A study published in JNCI found HPV vaccination to be non-cost-effective in the Netherlands due to low cervical cancer cases and deaths. The authors suggest vaccine price reduction could make it more cost-effective, but only if the vaccine's effectiveness increases.
A study published in The Lancet Oncology found that combining HPV testing with routine liquid-based cytology (LBC) screening in the UK did not increase the detection of cervical cancer. However, HPV testing detected cases of precancerous cervical cells in the first round of screening, but this effect was not sustained over two rounds.
A review of nearly 6,000 women found that lack of information and misconceptions about breast and cervical cancer significantly contribute to screening fear. The study recommends promoting education and targeting specific fears to increase uptake rates.